Fig. 6
From: Oncolytic adenoviruses expressing checkpoint inhibitors for cancer therapy
Intratumoral administration of OAd-TIGIT-Fc induces antitumor memory. a, b BALB/c mice were subcutaneously challenged with 1.5 × 106 CT26 cells (counted as day 1). When tumor sizes reached ~100 mm3, the mice were intratumorally injected with 50 μL of OAd-TIGIT-Fc (1 × 108 pfu per tumor) on days 8, 11, 14, 17, and 20. On day 38, seven OAd-TIGIT-Fc-treated mice achieved a CR. On day 69, age-matched naive mice (n = 7) and mice with a CR (n = 7) were rechallenged with CT26 tumor cells (b). Data are represented as mean ± SEM. Tumor growth for individual mice is shown (c). d Splenic T cells were collected from treatment-naive mice or OAd-TIGIT-Fc-treated mice 45 days after CR achievement to analyze the secretion of IFN-γ in response to CT26 cells in an ELISpot assay (n = 3). Data are represented as mean ± SD. (***p < 0.001)
